Ginkgo BioworksDNA
DNA
About: Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.
Employees: 1,218
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
188% more call options, than puts
Call options by funds: $22M | Put options by funds: $7.67M
6.17% more ownership
Funds ownership: 54.97% [Q2] → 61.14% (+6.17%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
32% less capital invested
Capital invested by funds: $314M [Q2] → $215M (-$99M) [Q3]
50% less funds holding
Funds holding: 313 [Q2] → 155 (-158) [Q3]
84% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 180
99% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 124
Research analyst outlook
We haven’t received any recent analyst ratings for DNA.
Financial journalist opinion
Based on 4 articles about DNA published over the past 30 days
Neutral
Business Wire
16 hours ago
SaponiQx, Probius, and Ginkgo Bioworks Unite to Revolutionize Vaccine Adjuvant Development
LEXINGTON, Mass. & FREMONT, Calif.--(BUSINESS WIRE)--SaponiQx, a leader in saponin-based adjuvant discovery, is pleased to announce a strategic collaboration with Probius, a pioneer in quantum molecular spectroscopy for AI-driven discovery, and Ginkgo Bioworks. This partnership, fully funded by the Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program, aims to accelerate the discovery and development of next-gen.
Neutral
PRNewsWire
1 week ago
Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors
Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics BOSTON , Jan. 13, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. This collaboration underscores Ginkgo's capacity to deploy high-throughput biological approaches to tackle the complex challenge set associated with development of therapies targeting solid tumors.
Neutral
GlobeNewsWire
1 week ago
Rapid Rise of Synthetic Biology Fuels Enzymatic DNA Synthesis Boom Across Biopharma and Genomics
Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "Enzymatic DNA Synthesis Market by Service, by Application, by End-User, and By Region" report has been added to ResearchAndMarkets.com's offering. The global enzymatic DNA synthesis market is estimated to be USD 0.296 billion in 2024 and is expected to reach USD 3.90 billion by 2035, with a CAGR of 26.43% during the forecast period 2025-2035.
Neutral
PRNewsWire
1 week ago
Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
BOSTON , Jan. 9, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 a.m.
Positive
Zacks Investment Research
1 month ago
All You Need to Know About Ginkgo Bioworks (DNA) Rating Upgrade to Buy
Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
PRNewsWire
1 month ago
Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program
Ginkgo Bioworks to apply its mammalian cell engineering expertise to develop new cell-based systems for treating and monitoring endocrine disorders BOSTON , Dec. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a subcontract of up to $9.4 million awarded in partnership with Carnegie Mellon University to develop bioelectronic cell-based devices aimed at diagnosing and treating hormone disorders. This initiative is part of the Advanced Research Projects Agency for Health's (ARPA-H) Resilient Extended Automatic Cell Therapies (REACT) program.
Neutral
Seeking Alpha
2 months ago
Ginkgo Bioworks: Unproven Transition But 2025 Is Looking Better
Ginkgo Bioworks reported solid Q3 results, but underlying performance was weaker than the financials suggest after accounting for meaningless non-cash revenue. Ginkgo's new business model focuses on upfront value creation and solutions which reduce friction in the customer acquisition process. While Ginkgo continues to introduce new tools and is landing customers with these products, it is too early to say whether Ginkgo will succeed as a CRO.
Neutral
Seeking Alpha
2 months ago
Ginkgo Bioworks: Not Enough Progress
Ginkgo Bioworks reported mixed Q3 results, with a $45 million one-time revenue boost masking underlying revenue growth issues. Despite cost cutting efforts, Ginkgo continues to report large losses, and $325 million of cash was burned in the first nine months of 2023. The balance sheet is weakening, and long-term revenue estimates have continued to move lower.
Neutral
Seeking Alpha
2 months ago
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q3 2024 Results Conference Call November 12, 2024 5:30 PM ET Company Participants Megan LeDuc - Manager, IR Jason Kelly - Founder, CEO & Director Mark Dmytruk - CFO Conference Call Participants Tejas Savant - Morgan Stanley Matt Sykes - Goldman Sachs John Kim - Bank of America Mark Massaro - BTIG Jacquie Kesa - TD Cowen Megan LeDuc Good evening. I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks.
Negative
Zacks Investment Research
2 months ago
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $2.40. This compares to loss of $3.60 per share a year ago.
Charts implemented using Lightweight Charts™